Constructive Bio

Executive Summary

Constructive Bio is a UK-based synthetic biology company founded in 2021 that has developed a proprietary platform using a fully recoded E. coli strain (Syn61) to incorporate over 300 non-canonical amino acids (ncAAs) into peptides and proteins via fermentation. By expanding the genetic code, the company enables the production of novel therapeutics with chemical properties inaccessible to natural biology, such as improved stability, bioavailability, and target specificity. The platform addresses key limitations of traditional peptide and protein drugs, including rapid degradation and off-target effects, by introducing unnatural amino acids that confer enhanced pharmacological profiles. Constructive Bio’s technology positions it at the forefront of the emerging field of genetic code expansion, with potential applications across drug discovery, biologics, and drug delivery. Currently operating at an early stage, Constructive Bio is focusing on demonstrating its platform’s capabilities through proof-of-concept studies and initial therapeutic candidates. The company has not yet disclosed specific pipeline assets or funding rounds, but its innovative approach has attracted interest from the synthetic biology and pharmaceutical communities. The main challenges ahead include scaling fermentation processes, validating the safety and efficacy of ncAA-containing therapeutics, and securing strategic partnerships for development. With the growing demand for differentiated biologic drugs, Constructive Bio’s technology could enable a new class of therapies, but near-term execution and capital requirements will determine its trajectory.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q3 2026Publication of Proof-of-Concept Data in Peer-Reviewed Journal60% success
• Q4 2026Pharmaceutical Partnership for Therapeutic Candidate Development40% success